Induction of anti-tumour immunity by suicide-gene-modified HPV-16- transformed hamster cells

International Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 470-475

  Vonka, V ^a   Sobotkova E ^a   Hamsikova E ^a   Smahel M ^a   Zak R ^a   Kitasato, H ^a,b   Sainerova H ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CELL TRANSFORMATION; GENETIC TRANSFORMATION; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; SYRIAN HAMSTER; TUMOR REJECTION; WART VIRUS;

ANIMALS; ANIMALS, NEWBORN; ANTIVIRAL AGENTS; CELL DIVISION; CELL LINE, TRANSFORMED; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CRICETINAE; GANCICLOVIR; GENES, RAS; HUMANS; KIDNEY; MESOCRICETUS; MICE; NEOPLASMS, EXPERIMENTAL; OPEN READING FRAMES; PAPILLOMAVIRIDAE; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; VIRUS INTEGRATION;

EID: 0031837187     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980729)77:3<470::AID-IJC26>3.0.CO;2-A     Document Type: Article

References (21)

1. BUBENÍK, J., ŠÍMOVÁ, J., VONDRYS, P., VONKA, R., KITASATO, H., BOŠTÍK, P. and VONKA, V., IL-2 as adjuvant for vaccination with cells malignantly converted by HPV-16 or 3-MC. Int. J. Oncol., 8, 477-481 (1996).
2. CULVER, K.W., MOORMAN, D.W., MULDOON, R.R., PAULSEN, R.M., JR., LAMSAM, J.L., WALLING, H.W. and LINK, C.J., JR., Toxicity and immunologic effects of in vivo retrovirus-mediated gene transfer of the herpes-simplex-thymidine-kinase gene into solid tumours. Cold Spring Harbor Symp. Quant. Biol., 59, 685-690 (1994).
3. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHI, H., OLDHELD, E.H. and BLAESE, R.M., In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science, 256, 1550-1552 (1992).
4. DE CLERCQ, E. and HOLÝ, A., Efficacy of (S)-I-(3-hydroxy-2-phpsohonyl-methoxy-propylcytosine) in various models of herpes-simplex-virus infection in mice. Antimicrob. Agents Chemother., 35, 701-706 (1991).
5. DILBER, M.S., ABEDI, M.R., BJÖRKSTRAND, B., CHRISTENSEN, B., GAHRTON, G., XANTHOPOULOS, K.G. and SMITH, C.I.E., Suicide-gene therapy for plasma cell tumours. Blood, 88, 2192-2200 (1996).
6. FREEMAN, S.M., RAMESH, R., SHASTRI, M., MUNISHI, A., JENSEN, A.K. and MARROGI, A.J., The role of cytokines in mediating the bystander effect using HSV-TK xenogenic cells. Cancer Lett., 92, 165-174 (1995).
7. GISSMANN, L., JOCHMUS, I., NINDL, I. and MÜLLER, M., Immune response in genital papillomavirus infections in women. Prospects for the development of a vaccine against cervical cancer. In: J.C. Bystryn, S. Ferrone and P. Livington (eds.), Specific immunotherapy of cancer with vaccines. Ann. N.Y. Acad. Sci., 690, 80-85 (1993).
8. KITASATO, H., VONKA, R., BOŠTÍK, P., HAMŠÍKOVÁ, E., SOBOTKOVÁ, E., ŠMAHEL, M. and VONKA, V., Properties of Syrian-hamster cells transformed by human papillomavirus type 16. Acta virol., 40, 281-288 (1996).
9. MARTIN, L.A. and LEMOINE, N.R., Direct cell killing by suicide genes. Cancer Metast. Rev., 15, 301-316 (1996).
10. MOOLTEN, F., WELLS, J.M., HEYMAN, R.A. and EVANS, R.M., Lymphoma regression induced by ganciclovir in mice bearing a herpes-thymidine transgene. Hum. Gene Ther., 1, 125-134 (1990).
11. RAMESH, R., MARROGI, A.J., MUNSHI, A., ABBOUD, C.N. and FREEMAN, S.M., In vivo analysis of the "bystander effect". A cytokine cascade. Exp. Hematol, 24, 829-838 (1996a).
12. RAMESH, R., MARROGI, A.J., MUNSHI. A., ABBOUD, C.N. and FREEMAN, S.M., Expression of co-stimulatory molecules: B7 and ICAM up-regulution after treatment with a suicide gene. Cancer Gene Ther., 3, 373-384 (1996b).
13. ROUBAL, J. and KLEIN, G., Synthesis of thymidine kinase (TK) in Epstein-Barr-virus-superinfected Raji TK-negative cells. Intervirology, 15, 43-48 (1981).
14. SCHILLER, J.T. and OKUN, M.M., Papillomavirus vaccines. Current status and future prospects. Advanc. Dermatol., 11, 355-381 (1996).
15. TINDLE, R.W., Human papillomavirus vaccines for cervical cancer. Current Opin. Immunol., 8, 643-850 (1996).
16. VAN DRIEL, W.J., RESSING, M.E., BRANDT, R.M.P., TOES, R.E.M., FLEUREN, G.J., TRIMROS, J.B., KAST, W.M. and MELIEF, C.J.M., The current status of therapeutic HPV vaccine. Ann. Med., 28, 471-477 (1996).
17. VILE, R.G., NELSON, J.A., CASTLEDEN, S., CHONG, H. and HART, L.R., Systemic gene therapy of marine melanoma using tissue-specific expression of the HSV TK gene involves an immune component. Cancer Res., 54, 6223-6234 (1994).
18. VONKA, V., Human papillomavirus vaccines. Fol. Biol., 42, 73-78 (1996).
19. WILSON, K.M., STAMBROOK, P.J., BI, W.L., PAVELIC, Z.P., PAVELIC, L. and GLUCKMAN, J.L., HSV-tk gene therapy in head-and-neck squamous-cell carcinoma. Enhancement by the local and distant bystander effect. Arch. Otolaryngol. Head Neck Surg., 122, 746-749 (1996).
20. ZÁVADA, V., ERBAN. V., ŘEZÁCOVÁ, D. and VONKA, V. Thymidine-kinase in cytomegalovirus-infected cells. Arch. Virol., 52, 333-339 (1976).
21. ZUR HAUSEN, H., Papillomavirus infections - a major cause of human cancers. Biochim. biophys. Acta, 1288, F56-F78 (1996).